VBL Therapeutics (VBLT) Tops Q3 EPS by 3c

November 10, 2016 7:06 AM EST
Get Alerts VBLT Hot Sheet
Trade VBLT Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

VBL Therapeutics (NASDAQ: VBLT) reported Q3 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15).

At September 30, 2016, the Company had cash, cash equivalents and short-term bank deposits totaling $48.9 million and working capital of $46.0 million. We expect that our cash, cash equivalents and short-term bank deposits will enable us to fund our operating expenses and capital expenditure requirements into 2019. Our cash position is expected to be sufficient for completion of our on-going Phase 3 clinical trial of VB-111 in rGBM, for a potential registration trial of VB-111 in ovarian cancer and to support the investment in the new Modiin facility.

For earnings history and earnings-related data on VBL Therapeutics (VBLT) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment